Tonight's Highlights: US-Iran Ceasefire Reached; Stock Futures Rally Across the Board, SpaceX Gains Over 6%
US equity index futures rallied in tandem on Monday following President Trump’s announcement that the United States and Iran have brokered a definitive agreement to end military hostilities.
European benchmarks marched broadly higher in sympathy.
Trump disclosed on social media late Sunday that the accord with Tehran is "now a done deal" and scheduled for formal execution this Friday, June 19. Iranian authorities concurrently verified that a memorandum of understanding for a ceasefire had been successfully reached.
The breakthrough followed an earlier exchange of fire between Israel and Hezbollah, which had briefly stoked sell-side anxieties on trading desks regarding whether the diplomatic timetable would hold.
In response to the easing geopolitical premium, Brent crude futures plunged over 5% to slide below the $83-per-barrel threshold, while WTI crude futures dropped 6%.
European natural gas prices similarly retreated sharply, while spot gold ticked up 3%.
As retreating energy prices systematically unwound localized inflation anxieties, sovereign bond yields pulled back globally. In the US, fixed-income desks swiftly dialed back implied probabilities for additional interest rate hikes this year, triggering a parallel softening in the US dollar.
This macro rotation had already begun brewing across global trading desks over the past several weeks, catalyzed by a steady stream of progress signals from the Trump administration.
However, market strategists cautioned that the geopolitical deal remains far from fundamentally ironclad.
The treaty will not be formally executed until this Friday, and sources familiar with the discussions note that highly contentious issues, such as Iran’s nuclear development program, have been strategically deferred to subsequent rounds of negotiations.
In corporate action, SpaceX advanced over 6% in pre-market trading, building on its historic 19% opening-day surge last Friday that propelled its market capitalization past the $2 trillion milestone.
"A blockbuster SpaceX IPO acts as a powerful macro leading indicator for a broader resurgence in investor appetite for innovation and secular technology growth verticals," noted Evan Schlossman, Partner at venture capital firm SuRo Capital.
"It directly reflects deep institutional liquidity, mindshare, and investment conviction targeting these frontier asset classes."
Separately, up-to-the-minute pre-market dispatches indicate that Nvidia is tracking to raise at least $20 billion via a multi-tranche investment-grade corporate bond offering.
Corporate & Global News
Musk: SpaceX Targets Near $1 Trillion in Revenue by 2030: Elon Musk stated June 14 on social media platform X that he projects SpaceX’s top-line revenue could hit roughly $1 trillion by 2030, adding, "I would be surprised if SpaceX revenue is under $1 trillion by 2031."
The aerospace pioneer made its official trading debut on the Nasdaq on June 12, pricing its historic IPO at $135 per share.
The 555.6-million-share float fetched a record-breaking $75 billion capital raise, valuing the entity at an initial $1.77 trillion baseline to print the largest initial public offering in US capital markets history.
Johnson & Johnson Commits Over $1 Billion to Expand US Vision Care Hub: Johnson & Johnson announced June 15 a capital deployment exceeding $1 billion to expand its flagship vision care manufacturing complex in Jacksonville, Florida.
The capital expenditure program is engineered to scale aggregate capacity for its ACUVUE contact lens product portfolio, encompassing the construction of a next-generation distribution network alongside the integration of advanced automation technologies.
Fox Corp. to Acquire Roku in $22 Billion Cash-and-Stock Deal: Fox Corp. has reportedly reached an agreement to acquire streaming hardware and platform operator Roku in a cash-and-stock transaction valued at $160 per share, implying an enterprise value of approximately $22 billion.
Following the disclosure, Fox shares plunged over 14% in heavy pre-market volume.
Merck’s RSV Preventative Monoclonal Antibody Approved in China: Merck announced June 15 that its long-acting monoclonal antibody injection, clesrovimab (marketed under the trade name Clesval®), has secured regulatory clearance from China's National Medical Products Administration (NMPA).
The biologic is approved for the prevention of lower respiratory tract infections caused by Respiratory Syncytial Virus (RSV) in neonates and infants entering or born during their first RSV season.